On April 20, 2017 Incyte Corporation (Nasdaq: INCY) reported that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, Illinois from June 2-6, 2017 (Press release, Incyte, APR 20, 2017, View Source [SID1234518648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presentations will include six abstracts from the ECHO-202/KEYNOTE-037 trial (NCT02178722), evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in various tumor types (two oral presentations, three poster discussions and one poster session). KEYTRUDA is marketed by Merck (known as MSD outside the United States and Canada).

Additionally, data from ECHO-204 (NCT02327078) evaluating the safety and efficacy of epacadostat in combination with Opdivo (nivolumab) have been accepted as an oral presentation. Bristol-Myers Squibb holds development and commercial rights to Opdivo globally except for in the Ono Pharmaceutical territories of Japan, South Korea and Taiwan.

"These abstracts highlight the depth and potential of our growing clinical development portfolio of both immuno-oncology and targeted therapies," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are especially pleased to have new data from the ECHO-202 trial evaluating epacadostat plus pembrolizumab and initial data from the ECHO-204 trial evaluating epacadostat plus nivolumab accepted. These data contributed to our recent decisions to initiate additional pivotal Phase 3 studies with Merck and BMS."

Select key abstracts and presentations include:
Immuno-oncology abstracts

Efficacy and Safety of Epacadostat Plus Pembrolizumab Treatment of NSCLC: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #9014, poster discussion)
Saturday, June 3, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board 340; Discussion 3:00 – 4:15 p.m. CT, Hall D2

Epacadostat Plus Pembrolizumab in Patients with Advanced RCC: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #4515, poster discussion)
Sunday, June 4, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #193; Discussion 11:30 – 12:45 p.m. CT, Arie Crown Theater

Efficacy/Safety of Epacadostat Plus Pembrolizumab in Triple-Negative Breast Cancer and Ovarian Cancer: Phase 1/2 ECHO-202 Study (Abstract #1103, poster session)
Sunday, June 4, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #95

Epacadostat Plus Pembrolizumab in Patients with Advanced Urothelial Carcinoma: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #4503, oral presentation)
Monday, June 5, 2017, 8:36 – 8:48 a.m. CT, Arie Crown Theater

Safety of Epacadostat 100 mg BID Plus Pembrolizumab 200 mg Q3W in Advanced Solid Tumors: Phase 2 Data from ECHO-202/KEYNOTE-037 (Abstract #3012, poster discussion)
Monday, June 5, 2017, 8:00 – 11:30 a.m. Hall A, Poster Board #107; Discussion 4:45 – 6:00 p.m. CT, Hall D1

Epacadostat Plus Nivolumab in Patients with Advanced Solid Tumors: Preliminary Phase 1/2 Results of ECHO-204 (Abstract #3003, oral presentation)
Monday, June 5, 2017, 2:15 – 2:27 p.m. CT, Hall D1

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors (Abstract #3005, oral presentation)
Monday, June 5, 2017, 2:39 p.m. – 2:51 p.m. CT, Hall D1

Epacadostat Plus Pembrolizumab in Patients with SCCHN: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #6010, oral presentation)
Tuesday, June 6, 2017, 8:12 – 8:24 a.m. CT, S100a

Targeted therapy abstract
Ongoing Phase 1/2 Study of INCB050465 for Relapsed/Refractory (R/R) B-Cell Malignancies (CITADEL-101) (Abstract #7530, poster session)
Monday, June 5, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #292
Full session details and data presentations at the ASCO (Free ASCO Whitepaper) 2017 annual meeting can be found here.